News
The intervention involves administering ceralasertib, an experimental drug, alongside Drugs X, Y, and Z. Ceralasertib is given twice daily for a week, while the other drugs are administered in single ...
2d
TipRanks on MSNAstraZeneca’s Phase I Study on Balcinrenone/Dapagliflozin: Key Insights for Investors
The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...
KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a further decision by the Singapore International Commercial Court (the "Court") to maintain the temporary injunction ...
Canagliflozin is generally well tolerated and improves blood sugar control in children and adolescents with type 2 diabetes, ...
NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt:PF0) a premier artificial intelligence (AI) company transforming clinical trials today announced the ...
Clinical Data Management Systems Market to Grow at 12% CAGR Driven by AI and Trial Expansion by 2030
The clinical data management systems market is expected to grow at a robust CAGR of 12% from 2025 to 2030. This growth is ...
The vitiligo treatment landscape is evolving with a shift towards targeted therapies, which have shown encouraging results in promoting repigmentatio ...
AstraZeneca and Viseven win the 2025 HBA ACE Awards for innovative workforce and community programmes shaping the future of ...
Innovations in supply chain management and the rise of direct-to-patient models are transforming how life sciences companies execute global clinical trials.
Likewise, Parexel, another of today’s top companies, was founded in 1982, and PPD was founded initially as a one-man consulting company in 19854,5.
The global clinical trial management system market size was US$ 1.4 billion in 2021. The global clinical trial management system market size is forecast to reach US$ 6.1 billion by 2032, growing at a ...
Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results